TD Asset Management
RXRX icon

TD Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

TD Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-32,534
Closed -$233K – 1509
2022
Q1 		$233K Sell
32,534
-18,900
-37% -$201K ﹤0.01% 1415
2021
Q4 		$881K Buy
51,434
+10,800
+27% +$203K ﹤0.01% 1298
2021
Q3 		$935K Hold
40,634
– – ﹤0.01% 1266
2021
Q2 		$1.23M Buy
+40,634
New +$1.2M ﹤0.01% 1214

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OMS
Obvious Management Services San Francisco, California $42.4M AUM 54.5% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

TD Asset Management's RXRX Position: Q2 2022 in Review

TD Asset Management sold out of Recursion Pharmaceuticals (RXRX) in Q2 2022, closing a stake of 32,534 shares — an estimated $233K sold.

TD Asset Management first reported a position in RXRX in Q2 2021 and held it in 4 quarters. The position peaked at $1.23M in Q2 2021. 133 funds tracked by Wall St. Rank hold RXRX as of Q2 2022.

  • TD Asset Management reported no remaining Recursion Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • TD Asset Management sold 32,534 Recursion Pharmaceuticals shares in Q2 2022, an estimated $233K.
  • TD Asset Management first reported a position in Recursion Pharmaceuticals in Q2 2021 and held it in 4 quarters.
  • TD Asset Management's Recursion Pharmaceuticals position peaked at $1.23M in Q2 2021.
  • 133 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2022.

Based on TD Asset Management's 13F filing for Q2 2022, filed 4 Aug 2022.